Reviewer ’s report  
 
Title: Danaparoid sodium -based anticoagulation therapy for port al vein thrombosis in cirrhosis 
patients  
 
Version: 0 Date: 10 Aug 2019  
 
Reviewer: Tomohiko Akahoshi  
 
Reviewer's report:  
 
This research was performed to examine the benefit of using Danaparoid sodium -based 
anticoagulation therapy in the patients who were suffered with PVT. Main point of this study is 
that combination therapy with AT -III is effective in the PVT patients with lower ATIII 
activity.However, there have been already some published report like this conclusion. In order to 
accept this paper, author should revise according to following suggestions .  
 
 
Major point  
 
1. This study is retorospective and single arm study. Since the small number of included 
patients, it is not enough evidence to recommend your proposal treatment of strategy as a 
first choiced therapy for PVT. Authors are now supposed to  use new strategy for PVT 
patients according to this work. If author compared presented cases with that of recent 
stratified strategy, author's conlusion should be strengthened. Please add more cases in 
your facilities.  
 
2. Some risk factors such as splen ectomy, post HCC therapy and congenital coagulopathy 
have been known. Please address possible causes of PVT. The causes should be 
addressed in Table 1.  
 
 
3. Partial PVT must be easier to dissolve by anticoagulant compared with completed 
obestrucrion PVT.  Author should compare the dimmisnished rate of partial and complete 
of PVT.  
 
 
Minor point  
 
1. Evaluation of PVT method is very important in this study. So please show how to 
measure the reduction rate by using software as a figure. I think it is difficult to measure 
PVT volume  in that soft.  
 
2. Please show anticoagulant therapy after PVT treatment.  Most patients are supposed to 
require anticoagulant therapy in out -patient clinics.  
 
Are the meth ods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the co nclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistica l review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, f ees, funding, or salary from an 
organisation that may in any way gain  or lose financial ly from the publication of this 
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation t hat may in any way gain or lose 
financially from the publication of this manuscript, either now or in the fut ure? 
 
3. Do you hold or are you currently applying for any patents  relating to the content of the 
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds or has applied for patents relating to the content of  the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
If you can answer no to all of the above, write 'I declare that I have  no competin g interests' 
below. If your reply is yes to any, please give details below.  
 
none  
 
I agree to the open peer review policy of the journal. I understan d that my name will be included 
on my report to the authors and, if the manuscript is acce pted f or publication, my named report 
including any attachments I upload will be posted on the website along with the authors' 
responses. I agree for my report to be made available under an Open Access Creative Commons 
CC-BY license ( http://creativecommons .org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be in cluded as confidential comments 
to the editor s, which will not be published.  
 
I agree to the open peer review policy of the journal  
Reviewer ’s report  
 
Title: Danaparoid sodium -based anticoagulation therapy for port al vein thrombosis in cirrhosis 
patients  
 
Version: 0 Date: 10 Aug 2019  
 
Reviewer: Tomohiko Akahoshi  
 
Reviewer's report:  
 
This research was performed to examine the benefit of using Danaparoid sodium -based 
anticoagulation therapy in the patients who were suffered with PVT. Main point of this study is 
that combination therapy with AT -III is effective in the PVT patients with lower ATIII 
activity.However, there have been already some published report like this conclusion. In order to 
accept this paper, author should revise according to following suggestions .  
 
 
Major point  
 
1. This study is retorospective and single arm study. Since the small number of included 
patients, it is not enough evidence to recommend your proposal treatment of strategy as a 
first choiced therapy for PVT. Authors are now supposed to  use new strategy for PVT 
patients according to this work. If author compared presented cases with that of recent 
stratified strategy, author's conlusion should be strengthened. Please add more cases in 
your facilities.  
 
2. Some risk factors such as splen ectomy, post HCC therapy and congenital coagulopathy 
have been known. Please address possible causes of PVT. The causes should be 
addressed in Table 1.  
 
 
3. Partial PVT must be easier to dissolve by anticoagulant compared with completed 
obestrucrion PVT.  Author should compare the dimmisnished rate of partial and complete 
of PVT.  
 
 
Minor point  
 
1. Evaluation of PVT method is very important in this study. So please show how to 
measure the reduction rate by using software as a figure. I think it is difficult to measure 
PVT volume  in that soft.  
 
2. Please show anticoagulant therapy after PVT treatment.  Most patients are supposed to 
require anticoagulant therapy in out -patient clinics.  
 
Are the meth ods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the co nclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistica l review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, f ees, funding, or salary from an 
organisation that may in any way gain  or lose financial ly from the publication of this 
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation t hat may in any way gain or lose 
financially from the publication of this manuscript, either now or in the fut ure? 
 
3. Do you hold or are you currently applying for any patents  relating to the content of the 
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds or has applied for patents relating to the content of  the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
If you can answer no to all of the above, write 'I declare that I have  no competin g interests' 
below. If your reply is yes to any, please give details below.  
 
none  
 
I agree to the open peer review policy of the journal. I understan d that my name will be included 
on my report to the authors and, if the manuscript is acce pted f or publication, my named report 
including any attachments I upload will be posted on the website along with the authors' 
responses. I agree for my report to be made available under an Open Access Creative Commons 
CC-BY license ( http://creativecommons .org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be in cluded as confidential comments 
to the editor s, which will not be published.  
 
I agree to the open peer review policy of the journal  
Please review this paper.
user
Reviewer ’s report  
 
Title: Danaparoid sodium -based anticoagulation therapy for port al vein thrombosis in cirrhosis 
patients  
 
Version: 0 Date: 10 Aug 2019  
 
Reviewer: Tomohiko Akahoshi  
 
Reviewer's report:  
 
This research was performed to examine the benefit of using Danaparoid sodium -based 
anticoagulation therapy in the patients who were suffered with PVT. Main point of this study is 
that combination therapy with AT -III is effective in the PVT patients with lower ATIII 
activity.However, there have been already some published report like this conclusion. In order to 
accept this paper, author should revise according to following suggestions .  
 
 
Major point  
 
1. This study is retorospective and single arm study. Since the small number of included 
patients, it is not enough evidence to recommend your proposal treatment of strategy as a 
first choiced therapy for PVT. Authors are now supposed to  use new strategy for PVT 
patients according to this work. If author compared presented cases with that of recent 
stratified strategy, author's conlusion should be strengthened. Please add more cases in 
your facilities.  
 
2. Some risk factors such as splen ectomy, post HCC therapy and congenital coagulopathy 
have been known. Please address possible causes of PVT. The causes should be 
addressed in Table 1.  
 
 
3. Partial PVT must be easier to dissolve by anticoagulant compared with completed 
obestrucrion PVT.  Author should compare the dimmisnished rate of partial and complete 
of PVT.  
 
 
Minor point  
 
1. Evaluation of PVT method is very important in this study. So please show how to 
measure the reduction rate by using software as a figure. I think it is difficult to measure 
PVT volume  in that soft.  
 
2. Please show anticoagulant therapy after PVT treatment.  Most patients are supposed to 
require anticoagulant therapy in out -patient clinics.  
 
Are the meth ods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the co nclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistica l review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, f ees, funding, or salary from an 
organisation that may in any way gain  or lose financial ly from the publication of this 
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation t hat may in any way gain or lose 
financially from the publication of this manuscript, either now or in the fut ure? 
 
3. Do you hold or are you currently applying for any patents  relating to the content of the 
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds or has applied for patents relating to the content of  the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
If you can answer no to all of the above, write 'I declare that I have  no competin g interests' 
below. If your reply is yes to any, please give details below.  
 
none  
 
I agree to the open peer review policy of the journal. I understan d that my name will be included 
on my report to the authors and, if the manuscript is acce pted f or publication, my named report 
including any attachments I upload will be posted on the website along with the authors' 
responses. I agree for my report to be made available under an Open Access Creative Commons 
CC-BY license ( http://creativecommons .org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be in cluded as confidential comments 
to the editor s, which will not be published.  
 
I agree to the open peer review policy of the journal  
assistant